Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease
Abstract
Aerosolized ribavirin was evaluated in the treatment of respiratory syncytial virus lower respiratory tract disease in 53 infants, 36 of whom had underlying diseases. Of the total infants, 26 were studied in a double-blind, placebo-controlled manner; 14 received ribavirin and 12 received placebo, a …
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
clinical trials as topic
humans
pubmed abstract
nih
national institutes of health
national library of medicine
Infant
newborn
Clinical Trial
Double-Blind Method
Random Allocation
controlled clinical trial
respiratory tract infections / complications
microbial sensitivity tests
c b hall
ribavirin / administration & dosage
ribavirin / therapeutic use*
respiratory tract infections / drug therapy*
respiratory syncytial viruses
respirovirus infections / drug therapy*
ribonucleosides / therapeutic use*
heart defects
oxygen / blood
pmid:3903239
j t mcbride
k c schnabel
bronchopulmonary dysplasia / complications*
congenital / complications*
respirovirus infections / complications
ribavirin / adverse effects
Access
Citation
ID:
116637
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
116637
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet